THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Latest Commentary
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What's your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
- Lucigen Corporation Awarded $2.8M SBIR Grant for Point of Care Diagnostics
- Blueprint Medicines Welcomes Fidelity Biosciences to Investor Syndicate
- Veloxis Pharmaceuticals announces a restructuring of the company to support and strengthen strategic focus on LCP-Tacro(TM) and announces changes to management
- Celldex's CDX-011 Demonstrates High Response Rates in Patients with Metastatic Breast Cancer Expressing Elevated Levels of GPNMB and in Triple Negative Disease
- More Press Releases
Featured Jobs
-
Entry Level Process Engineer and Lead Process Engineer
Foster Wheeler Biokinetics - San Francisco, CA -
Director, Pharmacovigilance and Drug Safety
TESARO - Waltham, MA -
Sr. IT Infrastructure Architect Job
Celgene Corporation - Berkeley Heights, NJ, US -
Microbiology Scientist
C3 Jian - Marina Del Rey, CA -
Sr. Director, Statistics Job
Celgene Corporation - Summit, NJ, US
Comments